Ovensa is a Canadian preclinical stage company committed to advance its siRNA lead candidate silencing galectin-1 overexpression in the tumor microenvironment to improve therapeutic outcomes of an immuno-oncology anti-PD-1 checkpoint inhibitor as a combination therapy in head & neck cancer. The company is also advancing its collaboration programs with pharmaceutical companies to develop precision and combination medicines through its proprietary TRIOZAN™ Platform for specific indications.
